These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

890 related items for PubMed ID: 30563566

  • 1. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
    Fromm G, de Silva S, Johannes K, Patel A, Hornblower JC, Schreiber TH.
    J Immunother Cancer; 2018 Dec 18; 6(1):149. PubMed ID: 30563566
    [Abstract] [Full Text] [Related]

  • 2. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
    Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA.
    Mol Cancer Ther; 2018 May 18; 17(5):1024-1038. PubMed ID: 29545330
    [Abstract] [Full Text] [Related]

  • 3. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, Gao Q, Li T, Shim JH, Zhang C, Liu K, Lee MH.
    Front Immunol; 2021 May 18; 12():654463. PubMed ID: 34054817
    [Abstract] [Full Text] [Related]

  • 4. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.
    Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH.
    Cancer Immunol Res; 2016 Sep 02; 4(9):766-78. PubMed ID: 27364122
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
    Kuang Z, Pu P, Wu M, Wu Z, Wang L, Li Y, Zhang S, Jing H, Wu W, Chen B, Liu J.
    Mol Cancer Ther; 2020 Dec 02; 19(12):2564-2574. PubMed ID: 32999045
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
    Roberts A, Bentley L, Tang T, Stewart F, Pallini C, Juvvanapudi J, Wallace GR, Cooper AJ, Scott A, Thickett D, Lugg ST, Bancroft H, Hemming B, Ferris C, Langman G, Robinson A, Chapman J, Naidu B, Pinkney T, Taylor GS, Brock K, Stamataki Z, Brady CA, Curnow SJ, Gordon J, Qureshi O, Barnes NM.
    Sci Rep; 2021 Feb 17; 11(1):4030. PubMed ID: 33597595
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.
    Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ, Weinberg AD.
    Mol Immunol; 2007 May 17; 44(12):3112-21. PubMed ID: 17374396
    [Abstract] [Full Text] [Related]

  • 20. OX40, OX40L and Autoimmunity: a Comprehensive Review.
    Webb GJ, Hirschfield GM, Lane PJ.
    Clin Rev Allergy Immunol; 2016 Jun 17; 50(3):312-32. PubMed ID: 26215166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.